Profound Medical to present TULSA-PRO data at SIR 2026 in Toronto, April 11-15

Profound Medical Corp.

Five oral presentations on April 12 during 'Men's Health 1' session at SIR Annual Meeting.
Categorical course 'Prostate Interventions: TULSA and Beyond' on April 13 featuring TULSA.
Presentations include CAPTAIN trial data comparing TULSA vs robotic prostatectomy for intermediate-risk prostate cancer.
Other topics: TULSA for recurrent prostate cancer, extreme apex cancer, and automated segmentation validation.
CEO says growing acceptance of TULSA as mainstream treatment for prostate disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.